Evidence suggested children could play a larger role in community spread of COVID-19
On Aug. 20, 2020, in the most comprehensive study of COVID-19 pediatric patients to date, Harvard Medical School…
On Aug. 20, 2020, in the most comprehensive study of COVID-19 pediatric patients to date, Harvard Medical School…
On Aug. 19, 2020, Johnson & Johnson announced an agreement to acquire Momenta Pharmaceuticals, a company that discovers…
On Aug. 11, 2020, Moderna announced that the U.S. government had secured 100 million doses of mRNA-1273. The…
On Aug. 4, 2020, Yale University announced it was among the core partners of the new Center for…
On Jul. 28, 2020, Moderna announced a preclinical study evaluating mRNA-1273, its vaccine candidate against COVID-19, was published…
On Jul. 27, 2020, the National Institutes of Health (NIH) announced that a phase 3 clinical trial designed…
On Jul. 27, 2020, Moderna announced that the Phase 3 study of its mRNA vaccine candidate (mRNA-1273) against…
On Jul. 26, 2020, Moderna announced a modification to its contract with the Biomedical Advanced Research and Development…
On Jul. 21, 2020, National Institutes of Health (NIH) researchers reported early results from the first COVID-19 vaccine…
On Jul. 21, 2020, researchers from the National Institutes of Health (NIH) announced that early results from the…
On Jul. 14, 2020, Moderna announced the publication of an interim analysis of the open-label Phase 1 study…
On Jul. 9, 2020 Moderna and Laboratorios Farmaceuticos Rovi announced a collaboration for large-scale, commercial fill-finish manufacturing of…
On Jul. 8, 2020, Moderna announced that it had completed enrollment for both cohorts of the Phase 2…
On Jul. 8, 2020, Constant Therapeutics reported that its peptide drug TXA127 was tested in a series of…
On Jun. 25, 2020 Moderna announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine…
On Jun. 11, 2020, Moderna announced progress on late-stage development of mRNA-1273, the Company’s mRNA vaccine candidate against…
On May 29, 2020, Moderna announced the first participants in each age cohort had been dosed in the…
On May 28, 2020, Biogen and the Lemelson-MIT Program (LMIT) at the Massachusetts Institute of Technology announced the…
On May 18, 2020, Moderna announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus…
On May 13, 2020, the Massachusetts Consortium on Pathogen Readiness (MassCPR), a multi-institutional initiative convened by Harvard Medical…
On May 12, 2020, Moderna announced the U.S. Food and Drug Administration (FDA had granted Fast Track designation…
On May 12, 2020, the Broad Instituteメs Drug Repurposing Hub announced that it had opened its repository of…
On May 5, 2020, Massachusetts Eye and Ear and Massachusetts General Hospital (MGH), members of Mass General Brigham,…
On May 5, 2020, a team of researchers at the McGovern Institute for Brain Research at MIT, the…
On May 1, 2020, Moderna and Lonza announced a 10-year strategic collaboration agreement to enable larger scale manufacture…
On Apr. 27, 2020, Yield10 Bioscience announced it has obtained a positive response from USDA-APHIS’s Biotechnology Regulatory Services…
On Apr. 27, 2020, Moderna announced it had submitted an Investigational New Drug application to the U.S. Food…
On Apr. 22, 2020, researchers at Massachusetts Institute of Technology (MIT); the Ragon Institute of MGH, and Harvard…
On Apr. 16, 2020, Biogen, Broad Institute of MIT and Harvard, and Partners HealthCare announced a consortium that…
On Apr. 16, 2020, Moderna announced an agreement for a commitment of up to $483 million from the…